Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Less than three weeks from being added to the Nasdaq Biotechnology Index and moving to the Nasdaq Global Select Market as its stock price stagnated around $20, Epizyme, Inc. ($EPZM) found legs on
Shares of Pharmacyclics, Inc. ($PCYC) are on the run Tuesday after and Independent Data Monitoring Committee said that a Phase III trial of Imbruvica (ibrutinib) should be stopped early because it